TY - JOUR
T1 - KRAS controls pancreatic cancer cell lipid metabolism and invasive potential through the lipase HSL
AU - Rozeveld, Cody N.
AU - Johnson, Katherine M.
AU - Zhang, Lizhi
AU - Razidlo, Gina L.
N1 - Funding Information:
This research was supported by the Mayo Clinic SPORE in Pancreatic Cancer (P50 CA102701), the Mayo Clinic Center for Cell Signaling in Gastroenterology (P30 DK084567), the Mayo Clinic Cancer Center (P30 CA015083), the NCI (R01 CA104125), the Hirshberg Foundation for Pancreatic Cancer Research, the Mayo Clinic Center for Biomedical Discovery, and the Mayo Clinic Graduate School of Biomedical Sciences (to C.N. Rozeveld). We acknowledge Dr. Marina Pasca di Magliano for the inducible KRAS cell line (iKRAS), Dr. David Tuveson for the mouse KPC cell line (mKPC), and Dr. Kun Ling, Dr. Gregory Gores, Dr. Eugenia Trushina, Dr. Jason Doles, and Camden Daby for reagents, equipment, and technical support. We thank Mark McNiven, all members of the McNiven lab, and O. Kuiper for technical support, helpful insight, and fortitude.
Funding Information:
G.L. Razidlo reports grants from NCI, Hirshberg Foundation for Pancreatic Cancer Research, and NIH during the conduct of the study. No potential conflicts of interest were disclosed by the other authors.
Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2020/11/15
Y1 - 2020/11/15
N2 - Oncogene-induced metabolic reprogramming is a hallmark of pancreatic cancer (PDAC), yet the metabolic drivers of metastasis are unclear. In PDAC, obesity and excess fatty acids accelerate tumor growth and increase metastasis. Here, we report that excess lipids, stored in organelles called lipid droplets (LD), are a key resource to fuel the energy-intensive process of metastasis. The oncogene KRAS controlled the storage and utilization of LD through regulation of hormone-sensitive lipase (HSL), which was downregulated in human PDAC. Disruption of the KRAS-HSL axis reduced lipid storage, reprogrammed tumor cell metabolism, and inhibited invasive migration in vitro and metastasis in vivo. Finally, microscopy-based metabolic analysis revealed that migratory cells selectively utilize oxidative metabolism during the process of migration to metabolize stored lipids and fuel invasive migration. Taken together, these results reveal a mechanism that can be targeted to attenuate PDAC metastasis. Significance: KRAS-dependent regulation of HSL biases cells towards lipid storage for subsequent utilization during invasion of pancreatic cancer cells, representing a potential target for therapeutic intervention.
AB - Oncogene-induced metabolic reprogramming is a hallmark of pancreatic cancer (PDAC), yet the metabolic drivers of metastasis are unclear. In PDAC, obesity and excess fatty acids accelerate tumor growth and increase metastasis. Here, we report that excess lipids, stored in organelles called lipid droplets (LD), are a key resource to fuel the energy-intensive process of metastasis. The oncogene KRAS controlled the storage and utilization of LD through regulation of hormone-sensitive lipase (HSL), which was downregulated in human PDAC. Disruption of the KRAS-HSL axis reduced lipid storage, reprogrammed tumor cell metabolism, and inhibited invasive migration in vitro and metastasis in vivo. Finally, microscopy-based metabolic analysis revealed that migratory cells selectively utilize oxidative metabolism during the process of migration to metabolize stored lipids and fuel invasive migration. Taken together, these results reveal a mechanism that can be targeted to attenuate PDAC metastasis. Significance: KRAS-dependent regulation of HSL biases cells towards lipid storage for subsequent utilization during invasion of pancreatic cancer cells, representing a potential target for therapeutic intervention.
UR - http://www.scopus.com/inward/record.url?scp=85100087768&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100087768&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-20-1255
DO - 10.1158/0008-5472.CAN-20-1255
M3 - Article
C2 - 32816911
AN - SCOPUS:85100087768
SN - 0008-5472
VL - 80
SP - 4332
EP - 4345
JO - Cancer research
JF - Cancer research
IS - 22
ER -